Beverly Wilshire Ltd. Q3 2025 Financial Review: A Turnaround in Progress

Beverly Wilshire Ltd., a Singapore-listed company primarily engaged in aesthetic medical and healthcare services, has released its condensed interim consolidated financial statements for the third quarter and nine months ended 30 September 2025. This review highlights key financial metrics, recent performance trends, and notable corporate developments, providing investors with a structured view of the company’s current position and outlook.

Key Financial Metrics and Performance Comparison

Historical Performance Trends

• The company reported a net profit of S\$129K for the nine months ended 30 September 2025, reversing a net loss of S\$3.15M in the same period last year.
• Revenue for the nine months rose 56% YoY to S\$6.97M, driven entirely by growth in the aesthetic medical and healthcare segment in Malaysia. Trading and distribution contributed no revenue.
• Gross profit margin remained robust at 56% versus 55% a year ago, indicating stable profitability despite scale-up.
• Administrative expenses declined by 21% YoY, reflecting cost control and operational streamlining.
• The Group’s net asset value per share improved from (0.844) cents at end-2024 to (0.301) cents as of Q3 2025, though still negative.

Exceptional Items and Fundraising Activities

• No impairment loss was recognized in 2025, unlike S\$1.34M in 2024.
• The company raised S\$1.6M via new share issuances, and converted S\$754K of debt to equity, easing near-term liquidity pressures.
• Significant reduction in current liabilities (down 34% from end-2024), mainly due to lower payables and borrowings.
• The share base expanded sharply from 632.9M to 919.9M, mainly from equity fundraising and debt conversion.
• No dividends were declared; management cited operational and financial cash needs.

Chairman’s Statement

“The Group will continue to broaden and deepen its market presence, elevate its service offerings, as well as spearhead innovation. The Group will utilise its strengths, explore new opportunities, and stay current with industry trends, and will continue to launch new initiatives that will fuel growth and revolutionise customer experience in the medical aesthetics industry.”

Tone: The Chairman’s statement is distinctly optimistic, emphasizing expansion, innovation, and a positive outlook for the medical aesthetics sector.

Events Likely to Affect Performance

• The Group expects continued improvement in the Malaysian aesthetic segment and is planning further acquisitions to support revenue growth.
• Additional fundraising of >S\$2M via equity and debt instruments is intended, subject to approvals.
• A financial support undertaking from the controlling shareholder provides a backstop for liquidity over the next 18 months.
• No legal disputes, asset revaluations, or extraordinary expenses were noted for the period.

Corporate Actions

• Substantial equity issuance via placements and debt conversion, resulting in dilution but strengthening the balance sheet.
• No share buybacks or mandates; no treasury shares or related-party transactions were reported.
• No dividends proposed for the period.

Outlook and Forecast

• Management expects continued growth in Malaysia’s aesthetic segment, supported by positive industry trends and ongoing cost discipline.
• The global medical tourism market and Asia-Pacific aesthetics market are forecasted to grow at double-digit rates, supporting sector optimism.
• Liquidity concerns remain, with current liabilities exceeding current assets, but recent capital raising and shareholder support mitigate immediate risk.

Conclusion and Investment Recommendations

Performance Summary: Beverly Wilshire Ltd. has demonstrated a marked turnaround, moving from heavy losses to a modest profit, supported by strong revenue growth, cost reduction, and successful capital restructuring. However, the company remains in a net capital deficiency, and the business is highly dependent on continued fundraising and shareholder support for going concern.

• If you are currently holding this stock: Consider maintaining your position if you are comfortable with ongoing dilution and speculative turnaround risk. The operational trends are promising, but liquidity remains tight and further equity issuance is likely. Monitor future fundraising and acquisition developments closely.
• If you are not currently holding this stock: Exercise caution. While short-term financials have improved and sector dynamics are favourable, the company’s negative equity and reliance on fundraising indicate elevated risk. Wait for more sustained profitability and balance sheet improvement before considering entry.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisors before making any investment decisions. The analysis is based solely on the company’s official Q3 2025 financial report.

View B Wilshire Ltd Historical chart here